...cancer $89 Series B, C Abingworth Management, Brookside Capital, Deerfield Capital, Domain Associates, Omega Funds, Oxford Bioscience Partners...

...Capital and Deerfield Capital - as well as Omega Funds. Existing investors Abingworth, Domain Associates, Oxford Bioscience Partners...

...million Investors: RA Capital Management; Brookside Capital; Omega Funds; Deerfield Capital; Abingworth Management; Domain Associates; Oxford Bioscience Partners...

...Capital; Deerfield Capital; and Omega Funds also participated, along with existing investors Abingworth; Domain Associates; Oxford Bioscience Partners...

...with an emphasis on oncology, neurology and infectious disease. Baron was a general partner at Oxford Bioscience Partners...

...was with Korea Seoul Life Sciences Fund (KSLSF), whose GPs are Hanwha Venture Capital and Oxford Bioscience Partners...

...stake); The Wellcome Trust (13.4%); HealthCare Ventures (10.7%); BB Biotech Ventures (8.9%); Saints Capital (8.9%); Oxford Bioscience Partners...

...research grants and tax credits. Investors include Warburg Pincus (45.9% pre-IPO stake); Saints Capital (23.1%); Oxford Bioscience Partners...

...investment firm Saints Capital did a deal last week with early stage life sciences VC Oxford Bioscience Partners...
...The move will help free Oxford Bioscience to focus more on investing two new funds: Oxford Bioscience Partners...

...undisclosed targets in multiple disease areas. The company's VCs - Apax Partners , Abingworth Bioventures, Oxford Bioscience Partners...